The results show that Emulin™ alone is better than the leading prescription drug at reducing blood glucose levels in Type 2 diabetics
Winter Haven, FL (PRWEB) September 16, 2008
A newly developed plant extract can regulate blood sugar levels in Type 2 diabetics better than a leading prescription drug, according to the results of human trials released today.
The trial results involving Emulin™, an all-natural compound derived from tropical fruits, are even more significant now that major research shows just how critical it is for diabetics to control long-term blood sugar levels to stave off heart attacks and other complications of this disease.
"The results show that Emulin™ alone is better than the leading prescription drug at reducing blood glucose levels in Type 2 diabetics," said Daryl Thompson, a scientific director at ATM Metabolics , the Winter Haven Fla.-based firm that developed the food additive. "With the numbers of diabetics worldwide expected to grow from an estimated 150 million now to 300 million by 2025, the market for Emulin™ is staggering."
According to Thompson, the plant-derived compound acts like insulin when ingested. "We designed Emulin™ to lessen the glycemic impact of high-sugar foods like colas and candies or high-carbohydrate refined breads," Thompson said.
In a double-blind, placebo-controlled, FDA-approved human trial, 40 Type 2 diabetics consumed three time a day (before each meal) a capsule containing either 250 mg of Emulin™ or a placebo. Participants were divided into four sub-groups: placebo only; placebo and metformin, a leading prescription medication to control glucose absorption in Type 2 diabetics; Emulin™ only; and Emulin™ with metformin.
The study was discontinued after one week for the two groups taking metformin, and after two weeks for the other groups.
At the end of one week, fasting blood glucose levels remained the same or increased slightly for the placebo control group and decreased 2 percent in the metformin only group. Fasting blood glucose levels decreased 11 percent and 28 percent respectively, however, for the Emulin™ only group and the Emulin™ plus metformin group.
After one week, peak blood sugar level, meaning the level two hours after a glucose tolerance test, increased 4 percent in the placebo only group, was unchanged in the Emulin™ only group; and decreased 10 percent in the metformin only group and 12 percent in the metformin plus Emulin™ group.
At the end of two weeks, both fasting blood glucose and peak blood glucose had increased 1 percent in the placebo only group yet declined 20 percent in the Emulin™ only group.
The study results will be presented formally during the UCLA Symposium on Metabolic Diseases in January 2009. The independent company that conducted the human trial is dgd Research, Inc., of San Antonio, Texas.
About ATM Metabolics
ATM Metabolics is an early stage technology development and commercialization company focused on technologies for diabetic, nutrition, and diet products. The firm constantly researches and develops novel therapeutics for conditions that include Types 1 and 2 diabetes and other chronic or debilitating conditions. More information: http://www.atmmetabolics.com.
# # #